Incysus Therapeutics Treats First Patient in Phase 1 Study of Gamma Delta (γδ) T Cell Immunotherapy in Leukemia and Lymphoma Patients Undergoing Allogeneic Stem Cell Transplantation
May 12, 2020 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Fate Therapeutics Announces Issuance of U.S. Patent Protecting Enhanced Hematopoietic Stem Cell Compositions
October 05, 2016 08:00 ET
|
Fate Therapeutics, Inc.
Protects Cellular Composition of Lead Immunotherapy Product Candidate ProTmune™ Covers Compositions Generated Using Ex Vivo Modulation to Enhance Stem Cell Properties SAN DIEGO, Oct. 05, 2016 ...
Fate Therapeutics Receives FDA Orphan Drug Designation for ProTmune™ in Allogeneic Hematopoietic Cell Transplantation
September 26, 2016 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...